Synergistic SNGI-TKI combination against LSCs

Xiaoyan Jiang

doi:10.18632/aging.101272

Synergistic SNGI-TKI combination against LSCs

Aging (Albany NY). 2017 Jul 30;9(7):1643-1644. doi: 10.18632/aging.101272.

Author

Xiaoyan Jiang¹

Affiliation

¹ Terry Fox Laboratory, British Columbia Cancer Agency and Department of Medical Genetics, University of British Columbia; Vancouver, BC, Canada.

No abstract available

Keywords: BCR-ABL-T315I mutation; CML; Icaritin (SNG162 and SNG1153); cancer stem cells; drug-resistance; leukemic stem cells; tyrosine kinase inhibitors.

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Phytogenic / therapeutic use*
Drug Resistance, Neoplasm
Drug Synergism
Flavonoids / therapeutic use*
Humans
Leukemia / drug therapy*
Leukemia / pathology
Neoplastic Stem Cells / drug effects*
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors*

Substances

Antineoplastic Agents, Phytogenic
Flavonoids
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
icaritin